Strongbridge Biopharma plc announced that at the request of the Board of Directors, John H. Johnson has agreed to become the chief executive officer (CEO) of Strongbridge. Mr. Johnson, who has served as chairman of Strongbridge since March 2015, assumed the position of executive chairman in November 2019 to lead the organization while the Board conducted a formal search to identify a new CEO. Effective immediately, Mr. Johnson will assume the role of CEO of Strongbridge and remain a member of the Company’s Board of Directors. Mr. Johnson is a recognized leader in the biopharmaceutical industry with more than 30 years of experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone, and Pfizer Inc. Mr. Johnson currently serves as a director of Verastem Oncology. Mr. Johnson previously served on the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ. Mr. Johnson holds a B.S. from the East Stroudsburg University of Pennsylvania.